Wyeth names new chief executive
October 10, 2007Sales and Marketing Pfizer, Wyeth
Wyeth will begin 2008 with a new leader at the helm. Bernard Poussot will become the company's elected president and …
Gates Foundation invests $100m in unorthodox research
October 10, 2007Research and Development
Scientists with novel ideas for research into some of the world's biggest diseases are to be offered a new source …
Latest news from Datamonitor
October 9, 2007Research and Development
Critical Therapeutics starts Phase I trial of zileutonCritical Therapeutics has initiated a phase I clinical trial to assess the safety …
Wyeth buys Scottish biotech firm
October 8, 2007Research and Development
Wyeth is to acquire Haptogen, a biotech research company based in Aberdeen which has a unique approach to targeting the …
GSK appoints Witty to top job
October 8, 2007Sales and Marketing
GlaxoSmithKline has named JP Garnier's successor when he steps down as chief executive at the end of May next year.Andrew …
100m boost for NHS innovation
October 8, 2007A new body has been set up to promote innovation across the NHS and pharmaceutical products will form a key …
Eisai to appeal against Alzheimer’s court ruling
October 3, 2007Alzheimer's, Eisai, NICE
Eisai and Pfizer are to try once again to reverse NICE restrictions on Alzheimer’s drugs by appealing against the recent …
FDA rejects painkiller Prexige
October 3, 2007Sales and Marketing reg, safety
Novartis has received a "not approvable" letter from the FDA for its painkiller Prexige because of concerns about potential liver …
Roche cuts Tarceva price while NICE deliberate
October 3, 2007Roche has announced that it is to cut the price of its lung cancer treatment Tarceva for a limited time …
Latest news from Datamonitor
October 1, 2007Research and Development
Cubicin approved for marketing in CanadaCubist Pharmaceuticals has said that Health Canada has approved Cubicin for marketing in Canada, where …
Finding top people for the top job
October 1, 2007Business Services careers, management, recruitment
When it comes to filling the most senior roles in a company, whatever its size, executive search is, more often …
Leukaemia drug enters phase III studies in MS
September 28, 2007Research and Development
Patients with multiple sclerosis could benefit from a drug currently used to treat leukaemia, with late-stage trials now commencing.Discovered by …
Society launches MS awareness campaign
September 28, 2007Medical Communications
The MS Society has launched a campaign to raise awareness of multiple sclerosis and the help the patient group can …
Regulators and pharma to join forces on drug safety monitoring
September 28, 2007Sales and Marketing reg, safety
Regulators, the pharma industry and academic institutions are to come together in a new global alliance to research drug side-effects. …
mXm launches event ROI Monitor
September 28, 2007Medical Communications
mXm Medical Communications has launched a new tool to measure the return on investment from communications activities at medical meetings.Its …
BMA resists plans for London polyclinics
September 28, 2007Recent government proposals to centralise London healthcare have met resistance among GPs. Independent trade union for doctors, the British Medical …
BMS makes $430m biotech acquisition
September 27, 2007Research and Development
Bristol-Myers Squibb has significantly advanced its strategy to move into biologics with the acquisition of US biotech Adnexus.The $430 million …
News roundup from Datamonitor
September 26, 2007Sales and Marketing
Alnylam and Merck end collaborationBiopharmaceutical company Alnylam Pharmaceuticals and Merck & Co. have mutually agreed to terminate their July 2006 …
UK clinical trials: on the mend?
September 26, 2007Research and Development UK, clinical trials, global, research
How clinical research is organised in the UK is essential to the success of Britain's pharma industry, and to the …
Global products for local people: tailoring your brand strategy
September 25, 2007Medical Communications, Sales and Marketing branding, global
Deciding which aspects of a global brand should be defined centrally and how much freedom there is in any given …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
